FDA's Next Steps on Epilepsy Drugs and Suicide

Man, we hate to say we told you so. Today, the Wall Street Journal reported that several manufacturers of anti-epileptic medications met with FDA officials in New York to try and convince the agency not to add warnings to product labeling on an increased risk if suicidality. During the closed-door meeting, three drug manufacturersâ€"GlaxoSmithKline (which markets the epilepsy drug Lamictal), Pfizer (Neurontin and Lyrica) and UCB (Keppra)â€"made presentations to FDA, according to the Journal. Despi